Working… Menu

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02335944
Recruitment Status : Completed
First Posted : January 12, 2015
Last Update Posted : October 14, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )